top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjcvp

At age 40, the associated lifetime risk of developing coronary heart disease is 48.6% among men and 31.7% among women.1 Despite advances in the field of non-invasive coronary artery testing and ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Mads E. Jørgensen, Charlotte Andersson, Anne-Marie Schjerning Olsen, Knud Juel, Poul Erik Mortensen, Erik Jørgensen, ...

Date : 01/07/2015
Ehjcvp

Furthermore, we report advantages and disadvantages of respiratory drugs (β2 agonists, anti-cholinergics, and corticosteroids) administration in COPD patients with CVD. cardiovascular ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Gianluca Campo, Rita Pavasini, Simone Biscaglia, Marco Contoli, Claudio Ceconi

Date : 01/07/2015
Ehjcvp

The WG contributes to most ESC guidelines with expertise on cardiovascular pharmacotherapy. [...]over the last 2 years the WG has beenor is stillinvolved in eight ESC guidelines. Gender differences ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Keld Kjeldsen

Date : 01/01/2015 Item size : 98083 bytes
Ehjcvp

When I graduated from New York University's School of Medicine in 1952, drugs available for the management of cardiovascular diseases were few and with the exception of nitroglycerine, which was ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Eugene Braunwald

Date : 01/01/2015